ALTO vs IONR

ALTO's deterministic health scores reveal significant concerns: a Piotroski F-Score of 2/9 indicates weak financial health, and the absence of an Altman Z-Score raises distress risk concerns. Despite this, the stock trades at a discount to its Graham Number ($3.38) and intrinsic value ($1.12), suggesting potential undervaluation. The recent earnings surprise history is volatile but highly positive in the most recent quarters, with a 75% Q/Q EPS growth and 149% YoY EPS growth. Strong price momentum—253% 1-year return and 294.9% 6-month return—reflects market optimism, supported by a strong-buy analyst consensus. However, the company's negative revenue growth (-1.90% YoY) and minimal profitability (1.45% profit margin) remain critical red flags. Price trades at a 37.9% premium to fair value estimate ($3.38), limiting near-term upside from a valuation perspective.

IONR presents a profile of a pre-revenue development company with a Piotroski F-Score of 4/9, indicating stable but mediocre financial health. While the balance sheet is exceptionally clean with zero debt and a high current ratio (8.59), the company is suffering from extreme operational losses with an operating margin of -655.13%. The valuation is distorted by a Price/Sales ratio of 452.34, reflecting a near-total lack of revenue. Technical trends are completely bearish (0/100), and long-term price performance is deeply negative, suggesting the market is discounting the company's ability to reach production.